RareResearch.AI
← Back to atlas

P216R

Category 5 — IDR ExclusionConflictingCytoplasmic · predictedEditorial
ProlineArginine at position 216 · N-terminal cytoplasmic domain (87-313) · WFS1 (Wolframin)

Proline → Arginine at position 216 in N-terminal cytoplasmic domain. ClinVar Conflicting including monogenic diabetes, Cataract 41, Wolfram. AlphaMissense 0.11 (below threshold) — AM under-call. DynaMut2 ΔΔG +0.20. pLDDT 41 — Category 5 IDR!

Interactive 3D Structure

Wild-type reference
Wild-type P216 — native residue, no strong sidechain contacts
Fullscreen ↗
DynaMut2 mutant · P216R
Mutant R216 — energy-minimized; local contact network preserved
Fullscreen ↗

Computational Predictions

DynaMut2 ΔΔG
0.20kcal/mol
Stabilising — mild
AlphaMissense
0.105
LBen
AlphaFold pLDDT
41
model confidence
Schema
Cat 5
Category 5 — IDR Exclusion
ΔΔG confidence: Reduced confidence · Cytoplasmic
  • pLDDT 41.28 below 70

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditionsMonogenic diabetes; Cataract 41; Wolfram syndrome 1
InheritanceMulti-phenotype.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0063%
cDNA changec.647C>G
ClinVar accessionVCV000393386
Last evaluated2025/12/20 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Conflicting classifications of pathogenicity for WFS1-related diabetes (autosomal dominant); Cataract 41 (autosomal dominant, OMIM 116400); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.

  • WFS1-related diabetesautosomal dominantsubmitted as: Monogenic diabetes; Type 2 diabetes mellitus
  • Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1; Wolfram syndrome 1
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
  • Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0063% · 101 / 1,610,922 alleles
Homozygotes
0
Highest-frequency population
African / African American · AF 0.087%

Highest in African / African American: AF 0.087% (65 of 74,920 alleles), 13.8x the global figure. The global AF describes the general population, not the at-risk group.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
African / African American0.087%65 / 74,9200~1 in 580
Remaining individuals0.014%9 / 62,3440~1 in 3460
Admixed American0.0033%2 / 59,7900~1 in 14950
Finnish0.0032%2 / 63,0560~1 in 15760
European (non-Finnish)0.0020%23 / 1,179,3200~1 in 25640

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position 216 at pLDDT 41 — DEEP IDR. Sparse neighbors (GLY217, GLN215, ALA214). DynaMut2 untrustworthy.

P216R introduces charge + removes backbone constraint in disordered region. AM 0.11 under-call; multi-phenotype confirms clinical pathogenicity.

Amino-acid chemistry
Proline (P) → Arginine (R) — rigid helix-breaking replaced by long positively-charged amine.
Position in the protein
N-terminal cytoplasmic domain · position 216 IDR (pLDDT 41 — deep IDR).

Druggability Assessment

Category 5 — IDR Exclusion. pLDDT 41 deep IDR. AlphaMissense 0.11 below threshold. DynaMut2 prediction not trustworthy.

The Atlas routes Category 5 variants to wet-lab characterization. Multi-phenotype confirms clinical pathogenicity.

Why this matters

P216R is another deep-IDR variant in this batch — Atlas appropriately flags for wet-lab.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the P216R PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download P216R PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Region1321 · Interaction with ATP6V1A